 | | Vol. 12.01 – 15 January, 2021 |
| |
|
|
| The authors demonstrated that CRY1 expression was androgen-responsive and associated with poor outcome in prostate cancer. Functional studies and first-in-field mapping of the CRY1 cistrome and transcriptome revealed that CRY1 regulated DNA repair and the G2/M transition.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The IRE1α sulfonation-induced “regulated IRE1α-dependent decay” (RIDD) degraded miR-23b, enhancing the expression of NADPH oxidase 4 (NOX4). The expression of NOX4 was also upregulated in breast, and prostate cancer tissue.
[Redox Biology] |
|
|
|
| Scientists applied CLInt-Seq to identify T cell receptors (TCRs) reactive with peptide epitopes of prostatic acid phosphatase, which had been pursued by multiple groups as an immunotherapeutic target in prostate cancer.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Investigators observed that melatonin inhibited RANKL production in lung and prostate cancer cells by downregulating the p38 MAPK pathway, which in turn prevented cancer-associated osteoclast differentiation.
[Oncogene] |
|
|
|
| Scientists found that the antiandrogen Enzalutamide-resistant prostate cancer cells can be suppressed by hyper-physiological doses of the androgen DHT.
[Cell Death & Disease] |
|
|
|
| Researchers evaluated whether interactions between heterogenous populations could impact growth and response to radiotherapy in prostate cancer.
[Communications Biology] |
|
|
|
| To investigate whether combined treatment with Enzalutamide (ENZ) and 3,3′-diindolylmethane (DIM) could overcome ENZ resistance by regulating Wnt signaling to inhibit androgen receptor signaling and EMT in ENZ-resistant prostate cancer cells, 22Rv1 cells were cultured in normal medium and treated with ENZ, DIM, and DIM with ENZ.
[Scientific Reports] |
|
|
|
| The capacity of two androgen receptor (AR) isoforms to regulate splicing was examined. RNA-seq data from models that endogenously expressed AR and expressed AR-V7 in response to doxycycline were used.
[Scientific Reports] |
|
|
|
|
| The authors discuss the potential for genomic subtyping to improve prognostication and to help guide treatment selection. They summarize data on associations between androgen receptor (AR) pathway alterations and patient response to AR signaling inhibitors and other standards of care.
[Prostate Cancer and Prostatic Diseases] |
|
|
|
|
| EDAP TMS SA announced positive 24 month interim results from the “HIFI” study comparing outcomes from high intensity focused ultrasound (HIFU) versus radical prostatectomy in a population of prostate cancer patients.
[EDAP TMS] |
|
|
|
|
| January 25 – 28, 2021
Virtual |
|
|
|
|
|
| | Institute of Pharmacology and Structural Biology – Toulouse, France |
|
|
|
| | STEMCELL Technologies, Inc. – Burnaby, British Columbia, Canada |
|
|
|
| | Fondazione Human Technopole – Milan, Italy |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | Scripps Research Institute – La Jolla, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
